WO1993001861A1 - Method and apparatus for transcutaneous cardiac pacing - Google Patents

Method and apparatus for transcutaneous cardiac pacing Download PDF

Info

Publication number
WO1993001861A1
WO1993001861A1 PCT/US1991/004972 US9104972W WO9301861A1 WO 1993001861 A1 WO1993001861 A1 WO 1993001861A1 US 9104972 W US9104972 W US 9104972W WO 9301861 A1 WO9301861 A1 WO 9301861A1
Authority
WO
WIPO (PCT)
Prior art keywords
pacing
pulses
stimuli
amplitude
series
Prior art date
Application number
PCT/US1991/004972
Other languages
French (fr)
Inventor
Gary A. Freeman
Original Assignee
Zmd Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zmd Corporation filed Critical Zmd Corporation
Priority to EP9191915140A priority Critical patent/EP0594620A4/en
Priority to PCT/US1991/004972 priority patent/WO1993001861A1/en
Publication of WO1993001861A1 publication Critical patent/WO1993001861A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3625External stimulators

Definitions

  • This invention relates to electrically pacing the heart transcutaneously.
  • transcutaneous, or external, electrical pacing of a patient's heart electrical stimuli travel from the pacing apparatus' electrodes to the heart through the patient's skin and skeletal thorax muscles to stimulate the heart.
  • the skeletal muscles may contract in response to the passage of the electrical stimuli through them.
  • the passage of the electrical pacing stimuli through the patient's skin may stimulate cutaneous nerves and muscles located near to the skin. This nerve stimulation and skeletal muscle contraction may feel uncomfortable to the patient, or even become painful enough to result in the patient's intolerance of extended transcutaneous heart pacing.
  • the invention features pacing stimuli each of which comprises a series of pulses.
  • Each of the pulses is, by itself, incapable of causing a cardiac muscle contraction, but the series of pulses making up each pacing stimulus is capable, as a group, of causing such a contraction.
  • the series of pulses tends to produce less skeletal muscle stimulation than a continuous pulse, thus making extended transcutaneous pacing more bearable for a patient.
  • each pulse averages less than 0.5 msec (preferably less than 250 microseconds, and more preferably less than 50 microseconds) ; the duty cycle of the pulses (i.e., the percentage of time the pulse is on) is at least 20%, and more preferably at least 50%; and the amplitude of the pacing stimulus in the brief intervals between each pulse is below the minimum amplitude required for skeletal muscle stimulation if one were using a continuous pulse of the same duration as the pulse train (and is preferably substantially zero) .
  • the invention features reducing skeletal muscle stimulation during pacing by including in the pacing stimuli one or more pulses that have amplitudes below the threshold for skeletal muscle stimulation.
  • Stimulation threshold is here defined as the minimum pulse amplitude required for stimulation if the pulse amplitude of a given pulse train remained constant for the duration of the pulse train.
  • the subthreshold pulses tend to reduce the reaction of skeletal muscles to the above-threshold stimulus that follows them.
  • these subthreshold pulses are the initial pulses in a pacing stimulus itself comprising a series of pulses; the pacing stimulus extends for at least 5 msec (more preferably, at least 40 msec) ; and some, possibly all, of the subthreshold pulses, and possibly some of the above- threshold pulses, each has an amplitude that is greater than the amplitudes of the preceding pulses in the pacing stimulus.
  • the reduction in skeletal muscle stimulation is believed to result because the cardiac muscle reacts to the train of pulses as if it were one continuous pulse. whereas at least some of the skeletal muscles react in a manner more akin to the way they would react to individual pulses. It is believed that this difference may result from a filtering of the pulse train as it passes through the chest wall, with the result that the cardiac muscle sees a continuous stimulus, whereas at least some of the skeletal muscles are exposed to the unfiltered, or less filtered, pulses, which, because of their short duration, produce less skeletal muscle stimulation. But whatever physiological actions are actually responsible, the result is that, at cardiac threshold (i.e. at a stimulus amplitude just high enough to cause cardiac contraction) , the skeletal muscles are stimulated less by a train of pulses than by a continuous pulse.
  • cardiac threshold i.e. at a stimulus amplitude just high enough to cause cardiac contraction
  • the invention features providing background stimuli in the intervals between pacing stimuli to reduce discomfort during pacing.
  • the background stimuli occur only in the intervals between the pacing stimuli; the background stimuli comprise pulses; the average amplitude of the background pulses is less than the average amplitude of the pacing stimuli; the average amplitude of the background pulses is less than 20 mA (more preferably less than 10 mA) ; and the duty cycle of the background pulses is less than 80% (more preferably less than 50%) .
  • the invention features an electrode for transcutaneous pacing in which there are two skin-contacting regions each insulated and spaced laterally from the other.
  • Fig. 1 is a block diagram of a pacing stimuli signal generator according to one embodiment of the invention.
  • Fig. 2 is an illustrative example of electrical stimuli produced by the signal generator of Fig. 1.
  • Figs. 3A and 3B are illustrative examples of electrical pacing stimuli produced by the signal generator of Fig. 1.
  • Fig. 4 are plotted characteristics, one for cardiac muscle and one for skeletal muscle and cutaneous nerves, relating a stimulating pulse's strength with the pulse's duration.
  • Fig. 5 is an example of an electrode configuration for applying the electrical stimuli of Fig. 2 to a patient.
  • Figs. 6A-6C are three illustrative examples of alternative pacing stimuli produced by the signal generator of Fig. 1.
  • a signal generator 10 for generating electrical pacing stimuli 65 which are to be applied transcutaneously to a patient's heart.
  • the signal generator's timing and control circuitry 20 can accept cardiac feedback signals 12 from the patient to initiate electrical pacing stimuli, or it can operate without such feedback (asynchronous pacing) .
  • the timing and control circuitry also sets the timing characteristics of the pacing stimuli, as discussed below.
  • the timing and control circuitry 20 initiates the pacing stimuli by signaling the stimuli generating circuitry 30, which includes oscillator and drive circuitry 40, isolation circuitry 50, and waveform- shaping circuitry 60.
  • Oscillator and drive circuitry 40 generates a stream of pulses that are processed by isolation circuitry 50, which isolates the signal generator's internal voltages from the patient, thereby providing electrical hazard protection for the patient during the patient's exposure to the pacing stimuli 65.
  • Waveform-shaping circuitry 60 receives the isolation circuitry's pulse stream output and modifies signal characteristics of the pulse stream, e.g., pulse shape, polarity, and amplitude, to generate pacing stimuli 65 having user-specified signal parameters.
  • the pacing stimuli 65 are coupled to posterior and anterior electrodes 70, 72, which together externally deliver the electrical stimuli to the patient for transcutaneous pacing of the patient's heart.
  • the signal generator's electrical pacing stimuli output 65 is composed of pacing stimuli 80 and background pulse trains 90.
  • the pacing stimuli 80 comprising, for example, pacing pulse trains, are delivered to the patient to stimulate the patient's heart.
  • the background pulse trains 90 are delivered to the patient in the intervals between the pacing pulse trains, when the heart is not being stimulated.
  • pulse train stimuli provide effective transcutaneous stimulation of the heart with reduced patient discomfort.
  • the pacing pulse trains 80 each consist of a series of pulses, with each pulse having a time duration, or width, W , which may be different than the duration of the other pulses in the series.
  • characteristic curves for pulse stimuli representing the relationship between a pulse's current amplitude, or strength, i, and a pulse's duration, t, for stimulating cardiac muscle and skeletal muscle.
  • the duration, T t of each pacing pulse train 80 (Fig. 3) is chosen by considering these strength-duration curves.
  • Each curve delineates the minimum duration, t, which an electrical pulse stimulus having a given current amplitude, i, will require to stimulate a muscle. Stated another way, given a pulse amplitude, i, a muscle will not be stimulated unless the pulse duration, t, is on, or to the right of, the corresponding curve.
  • a minimum pulse amplitude, or rheobase (Ri c for cardiac muscle and Ri s for skeletal muscle) , defines the smallest pulse amplitude that will stimulate a muscle. Any stimulus having a current amplitude less than the rheobase will not stimulate a muscle, even if the pulse's duration is greater than the rheobase duration, called the utilization time, (Rt c for cardiac muscle and Rt s for skeletal muscle) . Comparing the strength-duration curves of Fig. 4, the cardiac muscle's utilization time, Rt c , which is greater than approximately 40 msec, is longer than that of skeletal muscle, having a utilization time Rt ⁇ which is considerably less than 40 msec.
  • a preferable range for the pacing pulse trains' durations T t is selected with the following consideration. While any stimulus point on the cardiac strength-duration curve produces effective cardiac stimulation, stimulus points having lower current amplitudes tend to produce lower skeletal muscle stimulation than stimulus points having higher current amplitudes, for a given stimulus duration. Accordingly, a pulse stimulus having the characteristics of point A (close to the cardiac utilization time Rt c ) stimulates skeletal muscle less than a pulse stimulus having the characteristics of point B, but will stimulate the heart equally effectively.
  • each pacing pulse train is therefore preferably at least 5 msec, or more preferably 20 msec, but may be of any duration sufficient to stimulate the heart.
  • the maximum preferable pacing pulse train duration is limited to approximately 150 msec because of safety considerations for inducing cardiac fibrillation.
  • the pulse width and pulse period T of each of the pulses in the pacing pulse trains are also selected based on a comparison of the strength-duration relationships for cardiac muscle and skeletal muscle (Fig. 4) .
  • a minimum pulse duration called the chronaxie (Ct_ for cardiac muscle and Ct_ for skeletal muscle)
  • Ct_ for cardiac muscle
  • Ct_ for skeletal muscle is the pulse duration corresponding to a stimulating pulse amplitude equal to twice the rheobase of a muscle.
  • the cardiac muscle's chronaxie Ct c is approximately equal to 2 msec and the skeletal muscle's chronaxie Ct s is approximately equal to 0.5 msec.
  • a pulse stimulus of a duration shorter than the skeletal muscle chronaxie Ct g having, e.g., the duration of a pulse at point C, would therefore tend not to stimulate either cardiac muscle or skeletal muscle.
  • a train of such pulses having suitably adjusted amplitudes and a pulse train duration T t which is longer than the cardiac muscle chronaxie Ct c , e.g., the stimulus duration of point A,. effectively stimulates the heart as if the pulse trains had been filtered by, e.g., the skeletal muscles, to produce a continuous pacing pulse.
  • the pulse width W of each of the pacing pulses is selected to be less, preferably much less, than the skeletal muscle chronaxie Ct g (0.5 msec). With pulses of such width, the skeletal muscles tend to be stimulated less than they would if the pacing pulse were a single continuous pulse, but the heart is stimulated as effectively as a continuous pulse.
  • the pacing pulse width for achieving this condition is preferably less than 100 microseconds, and most preferably less than 15 microseconds. Pulse widths of less than about 7 microseconds may produce a pacing pulse frequency which is high enough to cause tissue damage, and thus may need to be avoided.
  • the pacing pulse period T is selected to ensure adequate pacing stimulation, or capture, of the heart.
  • the preferred pacing pulse duty cycle is 66%, but a lower duty cycle, e.g., 20%, or a variable duty cycle may be used, provided the given duty cycle is adequate to capture the heart.
  • a lower duty cycle e.g. 20%
  • a variable duty cycle may be used, provided the given duty cycle is adequate to capture the heart.
  • the higher the duty cycle the higher will be the effective filtered amplitude of the continuous pulse that influences the cardiac muscle.
  • Fig. 3B A variation in the form of the pacing stimuli is shown in Fig. 3B.
  • the amplitude, i £ of the first pulse in each pacing pulse train has a subthreshold amplitude, i.e., the amplitude is below the minimum pulse amplitude required for stimulation if the pulse amplitude of a given pulse train remained constant for the duration of the pulse train.
  • Each of the pulses following the initial pulse has an amplitude greater than that of the previous pulses, with some number of trailing pulses all having a maximum current amplitude, i M .
  • the value of this maximum current amplitude i M is selected, along with other pulse train characteristics, e.g., pulse train duration, to ensure capture of the heart. For example, a pulse train with a given number of pulses having a maximum current amplitude i M may require a shorter duration to capture the heart than a pulse train with fewer pulses having a maximum current amplitude that is greater than i M
  • initial, subthreshold pulses, followed by a series of pulses each having an amplitude that is greater than the amplitudes of the preceding pulses is intended to induce accommodation of the skeletal muscles to the pacing pulse train stimuli.
  • Accommodation of a muscle is a physiological phenomenon which can be induced by gradually, rather than abruptly, exposing a muscle to a stimulus amplitude, whereby the stimulating threshold of the muscle is increased beyond the magnitude of the applied stimulus.
  • An accommodated muscle or nerve requires a higher than normal stimulus magnitude to be effectively stimulated, and may even reject stimulation altogether for any magnitude of stimulus increase.
  • the amplitudes of the pulses in the pacing pulse train are selected to cause accommodation of skeletal muscles but not to cause accommodation of cardiac muscle.
  • the pacing pulse trains effectively stimulate the heart but tend to decrease the skeletal muscle stimulation typically associated with the transcutaneous cardiac muscle stimulation.
  • the background pulse trains 90 are provided during the intervals between the pacing stimuli.
  • Each background pulse train comprises a series of pulses, with the amplitudes of the pulses alternating between a positive amplitude, i B , and a negative amplitude, -i B , in a biphasic fashion. While Fig. 2 shows each of the background pulses having the same amplitude magnitude, each of the pulses may have differing amplitudes.
  • the magnitude of the alternating amplitudes, [i B i is preferably below the minimum current amplitude which a pulse, having the width W B , would require to stimulate the skeletal muscles.
  • the background pulse train has an amplitude, e.g., zero amplitude, that is below the current amplitude required to stimulate skeletal muscle.
  • the pulse width W ⁇ and period T B of the background pulses are chosen to fulfill two criteria: 1.
  • the duty cycle (100 x 2W ⁇ /T B ) of the background pulses is preferably less than 80%, or more preferably less than 50%, for providing a low average current; and 2.
  • the average current (i B x duty cycle) is preferably less than 20 mA, and more preferably less than 10 mA.
  • the subthreshold stimulus from the background pulse trains 90 tends to reduce the pacing pulse trains' stimulation of the skeletal muscles, possibly through accommodation of those muscles. That is, by adding the background pulse trains, the discomfort from stimulation of skeletal muscle during cardiac pacing is less than it would be without the background pulses (when the pacing stimuli are at threshold) .
  • the background pulse characteristics are accordingly selected to enhance accommodation of the skeletal muscles while discouraging accommodation of the cardiac muscle.
  • the background pulse characteristics are selected to induce a level of skeletal muscle accommodation which increases - li ⁇ the muscle stimulation threshold above the largest pacing pulse train stimuli amplitude.
  • the background pulse trains and pacing pulse trains also decrease the cutaneous nerve stimulation associated with transcutaneous cardiac pacing. Because the skeletal muscles and cutaneous nerves have similar chronaxies (Fig. 4) , the cutaneous nerves, like skeletal muscles, tend to be stimulated less by the pulses in the pacing pulse trains than they would if the pacing pulse were a single continuous pulse. Furthermore, the background pulse train characteristics selected to produce accommodation of skeletal muscles accordingly produce accommodation of cutaneous nerves.
  • the signal generator's waveform-shaping circuitry 60 modifies the stream of pulses generated by the oscillator circuitry 40 to create and distinguish the pacing and background pulse trains in the pacing stimuli 65. This modification may require amplitude or polarity adjustment for the particular electrodes used with the signal generator, as discussed below.
  • the timing and control circuitry 20 provides further fine adjustment of the pacing pulse train characteristics, for example, pulse shape. Both the waveform-shaping circuitry 60 and the timing and control circuitry 20 may be programmed to include or omit any or more of the electrical signal characteristics discussed above.
  • a variety of electrode structures may be used to deliver the pacing stimuli.
  • the pacing stimuli are passed through the patient's thorax from the posterior electrode to the anterior electrode.
  • the contribution of the electrode configuration to stimulation reduction may be less important.
  • conventional noninvasive pacing electrodes with non etallic skin-contacting members such as those disclosed in U.S. Patent No. 4,349,030, or as sold by R-2, of Morton Grove, Illinois, Physio-Control Corporation, of Redmond, Washington, or ZMI Corporation, of Woburn, Massachusetts, are suitable for delivering the pacing pulse trains.
  • electrodes having metallic skin-contacting members may be adapted to deliver the pacing stimuli.
  • the anterior electrode 72 and posterior electrode 70 are adapted to deliver the pacing stimuli 65 from the signal generator 10 to a patient.
  • a variety of electrode structures may be adequately used to achieve this function.
  • the electrodes are configured so that pacing pulse trains are delivered through the skin and skeletal muscles to the heart, whereas background pulse trains, if existent, are delivered only to the skin and skeletal muscles, and not to the heart. This electrode configuration ensures that cardiac fibrillation will not be induced by the background pulse trains.
  • the electrodes 70, 72 are divided into central, isolated regions 70a, 72a, and surrounding annular regions 70b, 72b.
  • Each of the central regions is separated from its corresponding annular region by a distance which is adequate to provide electrical isolation between the two regions, e.g., at least one-quarter inch.
  • the lateral region within this separating distance may be filled with an adhesive to act as an insulating material between the inner and outer electrode regions.
  • the stimuli are passed through the patient's thorax from the posterior electrode's central region 70a to the anterior electrode's central region 72a.
  • the pacing stimuli never pass through the patient, but instead pass between the central and annular regions of each electrode, as shown in Fig. 5.
  • the polarity of, or direction in which, the background stimuli are applied to the patient through the electrodes may be suitably altered without decreasing the effectiveness of the pacing stimuli for pacing the patient's heart. If no background pulse trains are present, the entire stimuli may pass through the patient's thorax from one central region 70a (anode) to the other central region 72a (cathode) .
  • the pacing pulse train could have an initial pulse 81 with a maximum amplitude i M , followed by a series of pulses which each has an amplitude that is less than the amplitudes of all preceding pulses.
  • the pacing pulse train could have an initial portion 100 of subthreshold pulses, all of an equal amplitude, followed by a portion 105 of above-threshold pulses, all of an equal amplitude.
  • the initial portion 100 of subthreshold pulses may include a second portion of subthreshold pulses, all of a second, equal amplitude.
  • the pacing pulse train could have alternating subthreshold pulses 110 and above threshold pulses 120.
  • Another variation for achieving the subthreshold pulses is to vary the duration of the pulses, using shorter durations for the subthreshold pulses, and longer durations for the above-threshold pulses.
  • the pulses in a train could have non-rectangular shapes, e.g., triangular, exponential, or rounded.
  • the duty cycle and duration of pulses can be varied within the pulse train (e.g., there could be brief gaps in the sequence of pulses) .
  • the background pulses could also be used with conventional continuous pacing pulses, and could be applied continuously (even during the pacing stimuli) .
  • the background pulses could be monophasic. Individual background pulses could have non-rectangular shapes, e.g., triangular, exponential, or rounded.
  • the amplitude, duration, and duty cycle of the background pulses could vary over time. Gaps could be present in the train of background pulses. What is claimed is:

Abstract

Method and apparatus for transcutaneously pacing the heart with pacing stimuli each of which comprises a series of individual pulses. The heart reacts to the series of pulses as if the series were one continuous pulse, whereas the pulse series produces skeletal muscle reactions that are similar to that which would be expected for individual pulses. The result is reduced stimulation of skeletal muscles and nerves, and less discomfort for the patient. Further reduction in stimulation of skeletal muscles and nerves can be achieved by providing a series of subthreshold initial pulses in each pacing stimulus, and by providing background stimuli occurring in the intervals between pacing stimuli. The apparatus includes timing and control circuitry (20), stimuli generating circuitry (30) connected to electrodes (70, 72).

Description

METHOD AND APPARATUS FOR TRANSCUTANEOUS CARDIAC PACING
Background of the Invention This invention relates to electrically pacing the heart transcutaneously.
During transcutaneous, or external, electrical pacing of a patient's heart, electrical stimuli travel from the pacing apparatus' electrodes to the heart through the patient's skin and skeletal thorax muscles to stimulate the heart. Depending on the magnitude of the stimuli and the characteristics of a particular patient's skeletal muscles, the skeletal muscles may contract in response to the passage of the electrical stimuli through them. Similarly, the passage of the electrical pacing stimuli through the patient's skin may stimulate cutaneous nerves and muscles located near to the skin. This nerve stimulation and skeletal muscle contraction may feel uncomfortable to the patient, or even become painful enough to result in the patient's intolerance of extended transcutaneous heart pacing.
It has been shown (U.S. Patent No. 4,349,030) that the skeletal muscle contractions and cutaneous nerve stimulation associated with conventional transcutaneous heart pacing may be reduced by lengthening the duration of electrical pacing stimuli to greater than five milliseconds.
Summary of the Invention In a first aspect, the invention features pacing stimuli each of which comprises a series of pulses. Each of the pulses is, by itself, incapable of causing a cardiac muscle contraction, but the series of pulses making up each pacing stimulus is capable, as a group, of causing such a contraction. The series of pulses tends to produce less skeletal muscle stimulation than a continuous pulse, thus making extended transcutaneous pacing more bearable for a patient. In preferred embodiments, each pulse averages less than 0.5 msec (preferably less than 250 microseconds, and more preferably less than 50 microseconds) ; the duty cycle of the pulses (i.e., the percentage of time the pulse is on) is at least 20%, and more preferably at least 50%; and the amplitude of the pacing stimulus in the brief intervals between each pulse is below the minimum amplitude required for skeletal muscle stimulation if one were using a continuous pulse of the same duration as the pulse train (and is preferably substantially zero) . In a second aspect, the invention features reducing skeletal muscle stimulation during pacing by including in the pacing stimuli one or more pulses that have amplitudes below the threshold for skeletal muscle stimulation. Stimulation threshold is here defined as the minimum pulse amplitude required for stimulation if the pulse amplitude of a given pulse train remained constant for the duration of the pulse train. The subthreshold pulses tend to reduce the reaction of skeletal muscles to the above-threshold stimulus that follows them. In preferred embodiments, these subthreshold pulses are the initial pulses in a pacing stimulus itself comprising a series of pulses; the pacing stimulus extends for at least 5 msec (more preferably, at least 40 msec) ; and some, possibly all, of the subthreshold pulses, and possibly some of the above- threshold pulses, each has an amplitude that is greater than the amplitudes of the preceding pulses in the pacing stimulus.
The reduction in skeletal muscle stimulation is believed to result because the cardiac muscle reacts to the train of pulses as if it were one continuous pulse. whereas at least some of the skeletal muscles react in a manner more akin to the way they would react to individual pulses. It is believed that this difference may result from a filtering of the pulse train as it passes through the chest wall, with the result that the cardiac muscle sees a continuous stimulus, whereas at least some of the skeletal muscles are exposed to the unfiltered, or less filtered, pulses, which, because of their short duration, produce less skeletal muscle stimulation. But whatever physiological actions are actually responsible, the result is that, at cardiac threshold (i.e. at a stimulus amplitude just high enough to cause cardiac contraction) , the skeletal muscles are stimulated less by a train of pulses than by a continuous pulse.
In a third aspect, the invention features providing background stimuli in the intervals between pacing stimuli to reduce discomfort during pacing. In preferred embodiments, the background stimuli occur only in the intervals between the pacing stimuli; the background stimuli comprise pulses; the average amplitude of the background pulses is less than the average amplitude of the pacing stimuli; the average amplitude of the background pulses is less than 20 mA (more preferably less than 10 mA) ; and the duty cycle of the background pulses is less than 80% (more preferably less than 50%) .
In a fourth aspect, the invention features an electrode for transcutaneous pacing in which there are two skin-contacting regions each insulated and spaced laterally from the other.
Other features and advantages of the invention will be apparent from the following description of a preferred embodiment and from the claims.
Description of the Preferred Embodiment Fig. 1 is a block diagram of a pacing stimuli signal generator according to one embodiment of the invention.
Fig. 2 is an illustrative example of electrical stimuli produced by the signal generator of Fig. 1. Figs. 3A and 3B are illustrative examples of electrical pacing stimuli produced by the signal generator of Fig. 1.
Fig. 4 are plotted characteristics, one for cardiac muscle and one for skeletal muscle and cutaneous nerves, relating a stimulating pulse's strength with the pulse's duration.
Fig. 5 is an example of an electrode configuration for applying the electrical stimuli of Fig. 2 to a patient.
Figs. 6A-6C are three illustrative examples of alternative pacing stimuli produced by the signal generator of Fig. 1.
Referring to Fig. 1, there is shown a signal generator 10 for generating electrical pacing stimuli 65 which are to be applied transcutaneously to a patient's heart. The signal generator's timing and control circuitry 20 can accept cardiac feedback signals 12 from the patient to initiate electrical pacing stimuli, or it can operate without such feedback (asynchronous pacing) . The timing and control circuitry also sets the timing characteristics of the pacing stimuli, as discussed below. The timing and control circuitry 20 initiates the pacing stimuli by signaling the stimuli generating circuitry 30, which includes oscillator and drive circuitry 40, isolation circuitry 50, and waveform- shaping circuitry 60. Oscillator and drive circuitry 40 generates a stream of pulses that are processed by isolation circuitry 50, which isolates the signal generator's internal voltages from the patient, thereby providing electrical hazard protection for the patient during the patient's exposure to the pacing stimuli 65.
Waveform-shaping circuitry 60 receives the isolation circuitry's pulse stream output and modifies signal characteristics of the pulse stream, e.g., pulse shape, polarity, and amplitude, to generate pacing stimuli 65 having user-specified signal parameters. At the signal generator's output, the pacing stimuli 65 are coupled to posterior and anterior electrodes 70, 72, which together externally deliver the electrical stimuli to the patient for transcutaneous pacing of the patient's heart.
Referring to Fig. 2, the signal generator's electrical pacing stimuli output 65 is composed of pacing stimuli 80 and background pulse trains 90. The pacing stimuli 80, comprising, for example, pacing pulse trains, are delivered to the patient to stimulate the patient's heart. The background pulse trains 90 are delivered to the patient in the intervals between the pacing pulse trains, when the heart is not being stimulated.
Together, these pulse train stimuli provide effective transcutaneous stimulation of the heart with reduced patient discomfort.
Referring to Fig. 3A, the pacing pulse trains 80 each consist of a series of pulses, with each pulse having a time duration, or width, W , which may be different than the duration of the other pulses in the series.
Referring also to Fig. 4, there are shown characteristic curves for pulse stimuli, representing the relationship between a pulse's current amplitude, or strength, i, and a pulse's duration, t, for stimulating cardiac muscle and skeletal muscle. The duration, Tt, of each pacing pulse train 80 (Fig. 3) is chosen by considering these strength-duration curves. Each curve delineates the minimum duration, t, which an electrical pulse stimulus having a given current amplitude, i, will require to stimulate a muscle. Stated another way, given a pulse amplitude, i, a muscle will not be stimulated unless the pulse duration, t, is on, or to the right of, the corresponding curve. Two different stimulus points lying on the strength-duration curve for a muscle, like points A and B on the cardiac muscle curve, will equally effectively stimulate that muscle. A minimum pulse amplitude, or rheobase (Ric for cardiac muscle and Ris for skeletal muscle) , defines the smallest pulse amplitude that will stimulate a muscle. Any stimulus having a current amplitude less than the rheobase will not stimulate a muscle, even if the pulse's duration is greater than the rheobase duration, called the utilization time, (Rtc for cardiac muscle and Rts for skeletal muscle) . Comparing the strength-duration curves of Fig. 4, the cardiac muscle's utilization time, Rtc, which is greater than approximately 40 msec, is longer than that of skeletal muscle, having a utilization time Rtε which is considerably less than 40 msec.
Given these utilization times for cardiac and skeletal muscle, a preferable range for the pacing pulse trains' durations Tt is selected with the following consideration. While any stimulus point on the cardiac strength-duration curve produces effective cardiac stimulation, stimulus points having lower current amplitudes tend to produce lower skeletal muscle stimulation than stimulus points having higher current amplitudes, for a given stimulus duration. Accordingly, a pulse stimulus having the characteristics of point A (close to the cardiac utilization time Rtc) stimulates skeletal muscle less than a pulse stimulus having the characteristics of point B, but will stimulate the heart equally effectively. Therefore, by choosing a pulse train duration around the same duration as the cardiac utilization time, the heart can be adequately stimulated by the pulse train while producing less skeletal muscle stimulation than would be produced by a pulse train of shorter duration and correspondingly higher pulse current amplitudes. The total time duration, Tt, of each pacing pulse train is therefore preferably at least 5 msec, or more preferably 20 msec, but may be of any duration sufficient to stimulate the heart. The maximum preferable pacing pulse train duration is limited to approximately 150 msec because of safety considerations for inducing cardiac fibrillation.
The pulse width and pulse period T of each of the pulses in the pacing pulse trains are also selected based on a comparison of the strength-duration relationships for cardiac muscle and skeletal muscle (Fig. 4) . As shown in Fig. 4, a minimum pulse duration, called the chronaxie (Ct_ for cardiac muscle and Ct_ for skeletal muscle) , is the pulse duration corresponding to a stimulating pulse amplitude equal to twice the rheobase of a muscle. With a pulse stimulus having a duration shorter than the chronaxie, it becomes increasingly difficult to stimulate a corresponding muscle.
Considering the strength-duration curves of Fig. 4, the cardiac muscle's chronaxie Ctc is approximately equal to 2 msec and the skeletal muscle's chronaxie Cts is approximately equal to 0.5 msec. A pulse stimulus of a duration shorter than the skeletal muscle chronaxie Ctg, having, e.g., the duration of a pulse at point C, would therefore tend not to stimulate either cardiac muscle or skeletal muscle. However, a train of such pulses having suitably adjusted amplitudes and a pulse train duration Tt which is longer than the cardiac muscle chronaxie Ctc, e.g., the stimulus duration of point A,. effectively stimulates the heart as if the pulse trains had been filtered by, e.g., the skeletal muscles, to produce a continuous pacing pulse.
Referring again to Fig. 3, based on this consideration, the pulse width W of each of the pacing pulses is selected to be less, preferably much less, than the skeletal muscle chronaxie Ctg (0.5 msec). With pulses of such width, the skeletal muscles tend to be stimulated less than they would if the pacing pulse were a single continuous pulse, but the heart is stimulated as effectively as a continuous pulse. The pacing pulse width for achieving this condition is preferably less than 100 microseconds, and most preferably less than 15 microseconds. Pulse widths of less than about 7 microseconds may produce a pacing pulse frequency which is high enough to cause tissue damage, and thus may need to be avoided. Given the selected pulse width W , the pacing pulse period T is selected to ensure adequate pacing stimulation, or capture, of the heart. The preferred pacing pulse duty cycle is 66%, but a lower duty cycle, e.g., 20%, or a variable duty cycle may be used, provided the given duty cycle is adequate to capture the heart. Generally speaking, the higher the duty cycle, the higher will be the effective filtered amplitude of the continuous pulse that influences the cardiac muscle.
A variation in the form of the pacing stimuli is shown in Fig. 3B. The amplitude, i£, of the first pulse in each pacing pulse train has a subthreshold amplitude, i.e., the amplitude is below the minimum pulse amplitude required for stimulation if the pulse amplitude of a given pulse train remained constant for the duration of the pulse train. Each of the pulses following the initial pulse has an amplitude greater than that of the previous pulses, with some number of trailing pulses all having a maximum current amplitude, iM. The value of this maximum current amplitude iM is selected, along with other pulse train characteristics, e.g., pulse train duration, to ensure capture of the heart. For example, a pulse train with a given number of pulses having a maximum current amplitude iM may require a shorter duration to capture the heart than a pulse train with fewer pulses having a maximum current amplitude that is greater than iM.
The use of initial, subthreshold pulses, followed by a series of pulses each having an amplitude that is greater than the amplitudes of the preceding pulses is intended to induce accommodation of the skeletal muscles to the pacing pulse train stimuli. Accommodation of a muscle is a physiological phenomenon which can be induced by gradually, rather than abruptly, exposing a muscle to a stimulus amplitude, whereby the stimulating threshold of the muscle is increased beyond the magnitude of the applied stimulus. An accommodated muscle or nerve requires a higher than normal stimulus magnitude to be effectively stimulated, and may even reject stimulation altogether for any magnitude of stimulus increase. Given the physiological differences between cardiac muscle and skeletal muscle, the amplitudes of the pulses in the pacing pulse train are selected to cause accommodation of skeletal muscles but not to cause accommodation of cardiac muscle. By simultaneously achieving these conditions, the pacing pulse trains effectively stimulate the heart but tend to decrease the skeletal muscle stimulation typically associated with the transcutaneous cardiac muscle stimulation.
Referring again to Fig. 2, the background pulse trains 90 are provided during the intervals between the pacing stimuli. Each background pulse train comprises a series of pulses, with the amplitudes of the pulses alternating between a positive amplitude, iB, and a negative amplitude, -iB, in a biphasic fashion. While Fig. 2 shows each of the background pulses having the same amplitude magnitude, each of the pulses may have differing amplitudes. The magnitude of the alternating amplitudes, [iBi, is preferably below the minimum current amplitude which a pulse, having the width WB, would require to stimulate the skeletal muscles.
During the interval between each background pulse, the background pulse train has an amplitude, e.g., zero amplitude, that is below the current amplitude required to stimulate skeletal muscle. Given a particularly chosen amplitude between pulses, the pulse width Wβ and period TB of the background pulses are chosen to fulfill two criteria: 1. The duty cycle (100 x 2Wβ/TB) of the background pulses is preferably less than 80%, or more preferably less than 50%, for providing a low average current; and 2. For a given iB, Tβ, and WB combination, the skeletal muscles are minimally stimulated. The average current (iB x duty cycle) is preferably less than 20 mA, and more preferably less than 10 mA.
The subthreshold stimulus from the background pulse trains 90 tends to reduce the pacing pulse trains' stimulation of the skeletal muscles, possibly through accommodation of those muscles. That is, by adding the background pulse trains, the discomfort from stimulation of skeletal muscle during cardiac pacing is less than it would be without the background pulses (when the pacing stimuli are at threshold) .
Given the physiological differences between cardiac muscle and skeletal muscle, the background pulse characteristics are accordingly selected to enhance accommodation of the skeletal muscles while discouraging accommodation of the cardiac muscle. Preferably, the background pulse characteristics are selected to induce a level of skeletal muscle accommodation which increases - li ¬ the muscle stimulation threshold above the largest pacing pulse train stimuli amplitude. The background pulse trains 90, together with the pacing pulse trains 80, thereby tend to produce reduced stimulation of the skeletal muscles while simultaneously achieving effective stimulation of the heart.
The background pulse trains and pacing pulse trains also decrease the cutaneous nerve stimulation associated with transcutaneous cardiac pacing. Because the skeletal muscles and cutaneous nerves have similar chronaxies (Fig. 4) , the cutaneous nerves, like skeletal muscles, tend to be stimulated less by the pulses in the pacing pulse trains than they would if the pacing pulse were a single continuous pulse. Furthermore, the background pulse train characteristics selected to produce accommodation of skeletal muscles accordingly produce accommodation of cutaneous nerves.
Referring again to Fig. 1, the signal generator's waveform-shaping circuitry 60 modifies the stream of pulses generated by the oscillator circuitry 40 to create and distinguish the pacing and background pulse trains in the pacing stimuli 65. This modification may require amplitude or polarity adjustment for the particular electrodes used with the signal generator, as discussed below. The timing and control circuitry 20 provides further fine adjustment of the pacing pulse train characteristics, for example, pulse shape. Both the waveform-shaping circuitry 60 and the timing and control circuitry 20 may be programmed to include or omit any or more of the electrical signal characteristics discussed above.
A variety of electrode structures may be used to deliver the pacing stimuli. The pacing stimuli are passed through the patient's thorax from the posterior electrode to the anterior electrode. In view of the reduced skeletal muscle and cutaneous nerve stimulation that is achieved by the pacing and background stimuli, the contribution of the electrode configuration to stimulation reduction may be less important. Thus, conventional noninvasive pacing electrodes with non etallic skin-contacting members, such as those disclosed in U.S. Patent No. 4,349,030, or as sold by R-2, of Morton Grove, Illinois, Physio-Control Corporation, of Redmond, Washington, or ZMI Corporation, of Woburn, Massachusetts, are suitable for delivering the pacing pulse trains. Alternatively, electrodes having metallic skin-contacting members may be adapted to deliver the pacing stimuli.
Another suitable electrode configuration is shown in Fig. 5. The anterior electrode 72 and posterior electrode 70 are adapted to deliver the pacing stimuli 65 from the signal generator 10 to a patient. A variety of electrode structures may be adequately used to achieve this function. Preferably, the electrodes are configured so that pacing pulse trains are delivered through the skin and skeletal muscles to the heart, whereas background pulse trains, if existent, are delivered only to the skin and skeletal muscles, and not to the heart. This electrode configuration ensures that cardiac fibrillation will not be induced by the background pulse trains.
As shown in Fig. 5, in this configuration, the electrodes 70, 72 are divided into central, isolated regions 70a, 72a, and surrounding annular regions 70b, 72b. Each of the central regions is separated from its corresponding annular region by a distance which is adequate to provide electrical isolation between the two regions, e.g., at least one-quarter inch. The lateral region within this separating distance may be filled with an adhesive to act as an insulating material between the inner and outer electrode regions.
During delivery of a pacing pulse train, or the "pacing period," the stimuli are passed through the patient's thorax from the posterior electrode's central region 70a to the anterior electrode's central region 72a. During delivery of a background pulse train, or the "background period," the pacing stimuli never pass through the patient, but instead pass between the central and annular regions of each electrode, as shown in Fig. 5. The polarity of, or direction in which, the background stimuli are applied to the patient through the electrodes may be suitably altered without decreasing the effectiveness of the pacing stimuli for pacing the patient's heart. If no background pulse trains are present, the entire stimuli may pass through the patient's thorax from one central region 70a (anode) to the other central region 72a (cathode) .
Other embodiments of the invention are within the claims.
For example, referring to Fig. 6A, the pacing pulse train could have an initial pulse 81 with a maximum amplitude iM, followed by a series of pulses which each has an amplitude that is less than the amplitudes of all preceding pulses. As shown in Fig. 6B, the pacing pulse train could have an initial portion 100 of subthreshold pulses, all of an equal amplitude, followed by a portion 105 of above-threshold pulses, all of an equal amplitude. The initial portion 100 of subthreshold pulses may include a second portion of subthreshold pulses, all of a second, equal amplitude. Alternatively, as shown in Fig. 6C, the pacing pulse train could have alternating subthreshold pulses 110 and above threshold pulses 120. Another variation for achieving the subthreshold pulses is to vary the duration of the pulses, using shorter durations for the subthreshold pulses, and longer durations for the above-threshold pulses. Given any pulse combination in a pacing pulse train, the pulses in a train could have non-rectangular shapes, e.g., triangular, exponential, or rounded. The duty cycle and duration of pulses can be varied within the pulse train (e.g., there could be brief gaps in the sequence of pulses) .
The background pulses could also be used with conventional continuous pacing pulses, and could be applied continuously (even during the pacing stimuli) . The background pulses could be monophasic. Individual background pulses could have non-rectangular shapes, e.g., triangular, exponential, or rounded. The amplitude, duration, and duty cycle of the background pulses could vary over time. Gaps could be present in the train of background pulses. What is claimed is:

Claims

Claims 1. Apparatus for transcutaneously pacing the heart at a pacing rate, the apparatus comprising stimuli generating circuitry for generating electrical stimuli, and electrodes connected to the output of the stimuli generating circuitry for delivering the electrical stimuli to the patient, wherein said electrical stimuli include pacing stimuli delivered at the pacing rate, each pacing stimulus comprising a series of individual pulses.
2. The apparatus of claim 1 wherein each series of pulses is capable, as a group, of causing a contraction of the heart, but each individual pulse is incapable, by itself, of causing such a contraction.
3. The apparatus of claim 1 wherein said series of pulses extends for a duration of at least 5 msec.
4. The apparatus of claim 1 wherein the duration of the individual pacing pulses averages less than 0.5 msec.
5. The apparatus of claim 4 wherein said average pulse duration is less than 250 microseconds.
6. The apparatus of claim 5 wherein said average pulse duration is less than 50 microseconds.
7. The apparatus of either of claims 4, 5, or 6 wherein the duty cycle of said individual pulses is greater than 20%.
8. The apparatus of claim 7 wherein the duty cycle of said individual pulses is greater than 50%.
9. The apparatus of claim 1 wherein the amplitude of said pacing stimulus in the interval between individual pulses is less than the threshold amplitude for stimulating cardiac muscle.
10. The apparatus of claim 7 wherein the average amplitudes of said series of individual pacing pulses rise from a first amplitude to a second amplitude.
11. The apparatus of claim 10 wherein said first amplitude is less than the threshold for stimulation of skeletal muscle.
12. The apparatus of claim 11 wherein said second amplitude is reached in not less than 2 pulses.
13. Apparatus for transcutaneously pacing the heart at a pacing rate, the apparatus comprising stimuli generating circuitry for generating electrical stimuli, and electrodes connected to the output of the stimuli generating circuitry for delivering the electrical stimuli to the patient, wherein said electrical stimuli include pacing stimuli delivered at the pacing rate, each pacing stimulus comprising a plurality of pulses, with at least the initial pulse in each stimulus having an amplitude less than the threshold for causing contractions of skeletal muscle and cardiac muscle, and subsequent pulses have amplitudes greater than said threshold.
1 14. The apparatus of claim 13 wherein each
2 succeeding initial pulse has a generally greater
3 amplitude than the preceding pulses.
1 15. The apparatus of claim 1 wherein the series
2 of individual pulses is such that, at cardiac threshold
3 (i.e. when the pacing stimuli are adjusted to an
4 amplitude just high enough to cause cardiac
5 contractions) , there is less skeletal muscle stimulation
6 than would result using a continuous pulse having the
7 same duration as the series of pulses.
1 16. The apparatus of claim 1 wherein the series
2 of individual pulses is such that, at cardiac threshold
3 (i.e. when the pacing stimuli are adjusted to an
4 amplitude just high enough to cause cardiac
5 contractions) , there is less discomfort to the patient
6 than would result using a continuous pulse having the
7 same duration as the series of pulses.
1 17. A method of transcutaneously pacing the heart
2 at a pacing rate, the method comprising the steps of:
3 generating electrical pacing stimuli;
4 delivering the stimuli to a patient through
5 electrodes applied to the patient's chest;
6 wherein the pacing stimuli generated and delivered
7 to the patient comprise a series of individual pulses.
1 18. The method of claim 17 wherein each series of
2 pulses is capable, as a group, of causing a contraction
3 of the heart, but each individual pulse is incapable, by
4 itself, of causing such a contraction.
1.
19. The method of claim 17 wherein said series of
2 pulses extends for a duration of at least 5 msec.
20. The method of claim 17 wherein the duration of the individual pacing pulses averages less than 0.5 msec.
21. The method of claim 20 wherein said average pulse duration is less than 250 microseconds.
22. The method of claim 21 wherein said average pulse duration is less than 50 microseconds.
23. The method of either of claims 20, 21, or 22 wherein the duty cycle of said individual pulses is greater than 20%.
24. The method of claim 23 wherein the duty cycle of said individual pulses is greater than 50%.
25. The method of claim 17 wherein the amplitude of said pacing stimulus in the intervals between individual pulses is less than the pulse amplitude required for stimulating cardiac muscle if the pulse amplitude remained constant for the duration of the series of pulses.
26. The method of claim 23 wherein the average amplitudes of said series of individual pacing pulses rise from a first amplitude to a second amplitude.
27. The method of claim 26 wherein said first amplitude is less than the threshold for stimulation of skeletal muscle.
28. The method of claim 27 wherein said second amplitude is reached in not less than 2 pulses.
29. A method of transcutaneously pacing the heart at a pacing rate, the method comprising the steps of: generating electrical pacing stimuli; delivering the stimuli to a patient through electrodes applied to the patient's chest; wherein the pacing stimuli generated and delivered to the patient comprise a plurality of pulses, with at least the initial pulse in each stimulus having an amplitude less than the threshold for causing contractions of skeletal muscle and cardiac muscle, and subsequent pulses have amplitudes greater than said threshold.
30. The method of claim 29 wherein each succeeding initial pulse has a generally greater amplitude than the preceding pulses.
31. The method of claim 17 wherein the series of individual pulses is such that, at cardiac threshold (i.e. when the pacing stimuli are adjusted to an amplitude just high enough to cause cardiac contractions) , there is less skeletal muscle stimulation than would result using a continuous pulse having the same duration as the series of pulses.
32. The method of claim 17 wherein the series of individual pulses is such that, at cardiac threshold (i.e. when the pacing stimuli are adjusted to an amplitude just high enough to cause cardiac contractions) , there is less discomfort to the patient than would result using a continuous pulse having the same duration as the series of pulses.
33. Apparatus for transcutaneously pacing the heart at a pacing rate, the apparatus comprising stimuli generating circuitry for generating electrical stimuli, and electrodes connected to the output of the stimuli generating circuitry for delivering the electrical stimuli to the patient, wherein said stimuli generated and delivered to the patient include pacing stimuli occurring generally at the pacing rate, and having a shape and amplitude capable of causing contractions of the cardiac muscle, and background stimuli occurring at times other than said pacing stimuli, and having a shape and amplitude incapable of causing contractions of the cardiac muscle.
34. The apparatus of claim 33 wherein said background stimuli occur only at times other than said pacing stimuli.
35. The apparatus of claim 33 wherein each said background stimulus comprises a series of background pulses.
36. The apparatus of claim 35 wherein each said pacing stimulus comprises a series of pacing pulses.
37. The apparatus of claim 36 wherein the average amplitude of said background pulses is less than the average amplitude of said pacing stimuli.
38. The apparatus of claim 37 wherein the duty cycle of said background pulses is less than 80%.
39. The apparatus of claim 38 wherein said duty cycle is less than 50%.
40. The apparatus of claim 37 wherein said series of background pulses has an average current amplitude of less than 20 mA.
41. The apparatus of claim 40 wherein said series of background pulses has an average current amplitude of less than 10 mA.
42. The apparatus of claim 38 wherein each series of pulses is capable, as a group, of causing a contraction of the heart, but each individual pulse is incapable, by itself, of causing such a contraction.
43. The apparatus of claim 42 wherein the duration of the individual pacing pulses averages less than 0.5 msec.
44. The apparatus of claim 43 wherein the duty cycle of said individual pulses is at least 20%.
45. The apparatus of claim 43 wherein the amplitudes of said series of individual pacing pulses rise from a first amplitude to a second amplitude.
46. Electrodes for transcutaneous pacing, said electrodes comprising a first electrical terminal for making a connection to an external source of electrical current, a second electrical terminal for making a connection to an external source of electrical current, a first skin-contacting region electrically connected to said first terminal of the electrode, and a second skin-contacting region electrically insulated from said first region and spaced laterally from said first region and electrically connected to said second terminal of the electrode.
47. The electrodes of claim 46 wherein said first region laterally surrounds said second region.
48. The electrode of claim 47 wherein said second region is generally circular and said first region is generally annular.
49. A method of transcutaneously pacing the heart at a pacing rate, the method comprising the steps of: generating electrical stimuli; delivering the stimuli to a patient through electrodes applied to the patient's chest; wherein the stimuli generated and delivered to the patient include pacing stimuli occurring generally at the pacing rate, and having a shape and amplitude capable of causing contractions of the cardiac muscle, and background stimuli occurring at times other than said pacing stimuli, and having a shape and amplitude incapable of causing contractions of the cardiac muscle.
50. The method of claim 49 wherein said background stimuli occur only at times other than said pacing stimuli.
51. The method of claim 49 wherein each said background stimulus comprises a series of background pulses. 1 52. The method of claim 51 wherein each said
2 pacing stimulus comprises a series of pacing pulses.
1 53. The method of claim 52 wherein the average
2 amplitude of said background pulses is less than the
3 average amplitude of said pacing stimuli.
1 54. The method of claim 53 wherein the duty cycle
2 of said background pulses is less than 80%.
1 55. The method of claim 53 wherein said duty
2 cycle is less than 50%.
1 56. The method of claim 53 wherein said series of
2 background pulses has an average current amplitude of
3 less than 20 mA.
1 57. The method of claim 56 wherein said series of
2 background pulses has an average current amplitude of
3 less than 10 mA.
1 58. The method of claim 54 wherein each series of
2 pulses is capable, as a group, of causing a contraction
3 of the heart, but each individual pulse is incapable, by
4 itself, of causing such a contraction.
1 59. The method of claim 58 wherein the duration
2 of the individual pacing pulses averages less than 0.5
3 msec.
1.
60. The method of claim 59 wherein the duty cycle
2 of said individual pulses is at least 20%.
61. The method of claim 59 wherein the amplitudes of said series of individual pacing pulses rise from a first amplitude to a second amplitude.
62. The method of claim 49 wherein the pacing and background stimuli are delivered through electrodes whose configurations are different during the pacing and background stimulation intervals so that the background stimuli are, for the most part, not delivered through the chest but the pacing stimuli are delivered through the chest.
63. The method of claim 62 wherein one electrode is applied to either side of the chest, and the electrodes each comprise a first electrical terminal for making a connection to an external source of electrical current, a second electrical terminal for making a connection to an external source of electrical current, a first skin-contacting region electrically connected to said first terminal of the electrode, and a second skin-contacting region electrically insulated from said first region and spaced laterally from said first region and electrically connected to said second terminal of the electrode, and wherein the background stimuli are passed between the first and second skin-contacting regions of the same electrode, and the pacing stimuli are passed between from one electrode to the other electrode.
64. The electrodes of claim 63 wherein said first region laterally surrounds said second region.
PCT/US1991/004972 1991-07-15 1991-07-15 Method and apparatus for transcutaneous cardiac pacing WO1993001861A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP9191915140A EP0594620A4 (en) 1991-07-15 1991-07-15 Method and apparatus for transcutaneous cardiac pacing.
PCT/US1991/004972 WO1993001861A1 (en) 1991-07-15 1991-07-15 Method and apparatus for transcutaneous cardiac pacing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/004972 WO1993001861A1 (en) 1991-07-15 1991-07-15 Method and apparatus for transcutaneous cardiac pacing

Publications (1)

Publication Number Publication Date
WO1993001861A1 true WO1993001861A1 (en) 1993-02-04

Family

ID=22225671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004972 WO1993001861A1 (en) 1991-07-15 1991-07-15 Method and apparatus for transcutaneous cardiac pacing

Country Status (2)

Country Link
EP (1) EP0594620A4 (en)
WO (1) WO1993001861A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2280377A (en) * 1993-07-19 1995-02-01 Zmd Corp Method and apparatus for transcutaneous electrical cardiac pacing
US5792187A (en) * 1993-02-22 1998-08-11 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
WO1999061100A1 (en) * 1998-05-27 1999-12-02 Mower Morton M Augmentation of muscle contractility by biphasic stimulation
US6067470A (en) * 1998-03-05 2000-05-23 Mower Family Chf Treatment Irrevocable Trust System and method for multiple site biphasic stimulation to revert ventricular arrhythmias
US6136019A (en) * 1996-08-19 2000-10-24 Mower Family Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool
US6141586A (en) * 1996-08-19 2000-10-31 Mower Family Chf Treatment Irrevocable Trust Method and apparatus to allow cyclic pacing at an average rate just above the intrinsic heart rate so as to maximize inotropic pacing effects at minimal heart rates
US6178351B1 (en) 1996-08-19 2001-01-23 The Mower Family Chf Treatment Irrevocable Trust Atrial sensing and multiple site stimulation as intervention means for atrial fibrillation
US6295470B1 (en) 1996-08-19 2001-09-25 The Mower Family Chf Treatment Irrevocable Trust Antitachycardial pacing
US6539255B1 (en) 1998-07-16 2003-03-25 Cardiac Science, Inc. Full-tilt exponential defibrillation waveform
KR100451227B1 (en) * 2002-02-05 2004-10-02 엘지전자 주식회사 Method for sensorless rotary velocity control of synchronous reluctance motor
US7457662B2 (en) 2005-09-09 2008-11-25 Cardiac Science Corporation Method and apparatus for variable capacitance defibrillation
US7706864B2 (en) 1994-05-31 2010-04-27 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
US8447399B2 (en) 1996-08-19 2013-05-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US9089718B2 (en) 1997-03-07 2015-07-28 Cardiac Science Corporation Defibrillation system
GB2522717A (en) * 2014-02-04 2015-08-05 Team Turquoise Ltd A wearable heart entrainment device
US9144684B2 (en) 2009-07-02 2015-09-29 Galvani, Ltd. Medium voltage therapy applied as a test of a physiologic state
US9174061B2 (en) 2003-11-13 2015-11-03 Zoll Medical Corporation Multi-path transthoracic defibrillation and cardioversion
US9421391B2 (en) 2012-12-12 2016-08-23 Galvani, Ltd. Coordinated medium voltage therapy for improving effectiveness of defibrillation therapy
US10532181B2 (en) 2014-02-04 2020-01-14 Team Turquoise Ltd. Wearable apparatus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050695A (en) * 1959-09-10 1962-08-21 W W Henry Co Inc Pulse generator for human treatment
US4177817A (en) * 1978-02-01 1979-12-11 C. R. Bard, Inc. Dual terminal transcutaneous electrode
US4222386A (en) * 1979-03-26 1980-09-16 Smolnikov Leonid E Method for stimulating cardiac action by means of implanted _electrocardiostimulator and implantable electrocardiostimulator for effecting same
US4580570A (en) * 1981-01-08 1986-04-08 Chattanooga Corporation Electrical therapeutic apparatus
US4787389A (en) * 1987-07-16 1988-11-29 Tnc Medical Devices Pte. Ltd. Using an implantable antitachycardia defibrillator circuit

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5161529A (en) * 1988-12-02 1992-11-10 Intermedics, Inc. Cardiac pacemaker with capture verification

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050695A (en) * 1959-09-10 1962-08-21 W W Henry Co Inc Pulse generator for human treatment
US4177817A (en) * 1978-02-01 1979-12-11 C. R. Bard, Inc. Dual terminal transcutaneous electrode
US4222386A (en) * 1979-03-26 1980-09-16 Smolnikov Leonid E Method for stimulating cardiac action by means of implanted _electrocardiostimulator and implantable electrocardiostimulator for effecting same
US4580570A (en) * 1981-01-08 1986-04-08 Chattanooga Corporation Electrical therapeutic apparatus
US4787389A (en) * 1987-07-16 1988-11-29 Tnc Medical Devices Pte. Ltd. Using an implantable antitachycardia defibrillator circuit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0594620A4 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5431688A (en) * 1990-06-12 1995-07-11 Zmd Corporation Method and apparatus for transcutaneous electrical cardiac pacing
US5792187A (en) * 1993-02-22 1998-08-11 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
US6349233B1 (en) 1993-02-22 2002-02-19 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
GB2280377A (en) * 1993-07-19 1995-02-01 Zmd Corp Method and apparatus for transcutaneous electrical cardiac pacing
GB2280377B (en) * 1993-07-19 1997-04-02 Zmd Corp Method and apparatus for transcutaneous electrical cardiac pacing
US7706864B2 (en) 1994-05-31 2010-04-27 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
US6136019A (en) * 1996-08-19 2000-10-24 Mower Family Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool
US6141586A (en) * 1996-08-19 2000-10-31 Mower Family Chf Treatment Irrevocable Trust Method and apparatus to allow cyclic pacing at an average rate just above the intrinsic heart rate so as to maximize inotropic pacing effects at minimal heart rates
US6141587A (en) * 1996-08-19 2000-10-31 Mower Family Chf Treatment Irrevocable Trust Augmentation of muscle contractility by biphasic stimulation
US6178351B1 (en) 1996-08-19 2001-01-23 The Mower Family Chf Treatment Irrevocable Trust Atrial sensing and multiple site stimulation as intervention means for atrial fibrillation
US6295470B1 (en) 1996-08-19 2001-09-25 The Mower Family Chf Treatment Irrevocable Trust Antitachycardial pacing
US8447399B2 (en) 1996-08-19 2013-05-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US9089718B2 (en) 1997-03-07 2015-07-28 Cardiac Science Corporation Defibrillation system
US6067470A (en) * 1998-03-05 2000-05-23 Mower Family Chf Treatment Irrevocable Trust System and method for multiple site biphasic stimulation to revert ventricular arrhythmias
WO1999061100A1 (en) * 1998-05-27 1999-12-02 Mower Morton M Augmentation of muscle contractility by biphasic stimulation
AU749212B2 (en) * 1998-05-27 2002-06-20 Mr3 Medical Llc Augmentation of muscle contractility by biphasic stimulation
US6539255B1 (en) 1998-07-16 2003-03-25 Cardiac Science, Inc. Full-tilt exponential defibrillation waveform
KR100451227B1 (en) * 2002-02-05 2004-10-02 엘지전자 주식회사 Method for sensorless rotary velocity control of synchronous reluctance motor
US9174061B2 (en) 2003-11-13 2015-11-03 Zoll Medical Corporation Multi-path transthoracic defibrillation and cardioversion
US10022550B2 (en) 2003-11-13 2018-07-17 Zoll Medical Corporation Multi-path transthoracic defibrillation and cardioversion
US11097118B2 (en) 2003-11-13 2021-08-24 Zoll Medical Corporation Multi-path transthoracic defibrillation and cardioversion
US7962207B2 (en) 2005-09-09 2011-06-14 Cardiac Science Corporation Method and apparatus for variable capacitance defibrillation
US7457662B2 (en) 2005-09-09 2008-11-25 Cardiac Science Corporation Method and apparatus for variable capacitance defibrillation
US9144684B2 (en) 2009-07-02 2015-09-29 Galvani, Ltd. Medium voltage therapy applied as a test of a physiologic state
US9421391B2 (en) 2012-12-12 2016-08-23 Galvani, Ltd. Coordinated medium voltage therapy for improving effectiveness of defibrillation therapy
GB2522717A (en) * 2014-02-04 2015-08-05 Team Turquoise Ltd A wearable heart entrainment device
US10532181B2 (en) 2014-02-04 2020-01-14 Team Turquoise Ltd. Wearable apparatus
US11464939B2 (en) 2014-02-04 2022-10-11 Empathic Technologies Ltd. Wearable apparatus

Also Published As

Publication number Publication date
EP0594620A4 (en) 1994-11-02
EP0594620A1 (en) 1994-05-04

Similar Documents

Publication Publication Date Title
US5205284A (en) Method and apparatus for transcutaneous electrical cardiac pacing with background stimulation
US5193537A (en) Method and apparatus for transcutaneous electrical cardiac pacing
US5431688A (en) Method and apparatus for transcutaneous electrical cardiac pacing
WO1993001861A1 (en) Method and apparatus for transcutaneous cardiac pacing
US10173065B2 (en) Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US3738370A (en) Method of defibrillating a malfunctioning heart by means of electrodes located within the atrium
DE60104706T2 (en) UNIFORM, SUBCUTANEOUSLY IMPLANTABLE CARDIOVA TREATMENT DEFIBRILLATOR AND OPTIONAL PACEMAKER
US6711442B1 (en) Method and apparatus for reduction of pain from electric stimulation therapies
CA2703867C (en) Onset-mitigating high-frequency nerve block
EP0688579B1 (en) Device for heart therapy
EP0727241B1 (en) Device for heart stimulation
EP0253505B1 (en) Cardiac stimulator
US11083904B2 (en) Bisphasic or multiphasic pulse waveform and method
US20230264015A1 (en) Multi-electrode stimulation therapy with reduced energy
US7039466B1 (en) Spatial decimation stimulation in an implantable neural stimulator, such as a cochlear implant
EP0776678A1 (en) System for administering transcutaneous cardiac pacing with transcutaneous electrical nerve stimuli
WO2001010375A2 (en) Inhibition of action potentials
ZOLL et al. External and internal electric cardiac pacemakers
US20140200622A1 (en) Combination Device and Methods for Treating Congestive Heart Failure and Stroke
CN113457010A (en) Medical device and method for generating modulated high-frequency electrical stimulation pulses
US20080249584A1 (en) Method and device for cardiosympathetic inhibition
Konsten et al. Demonstration of the feasibility of implantation of a skeletal muscle pulse generator for fecal incontinence in a patient with an implanted unipolar DDD pacemaker
Sanders Jr et al. Ventricular fibrillation induction using nonsynchronized low energy external shock during rapid ventricular pacing: method of induction when fibrillation mode of ICD fails
Irnich The ideal pacemaker
Mushahwar et al. Interleaved dual-channel stimulation of the ventral lumbo-sacral spinal cord reduces muscle fatigue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA DE GB JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1991915140

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991915140

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1991915140

Country of ref document: EP